Celsion Corporation to Hold First Quarter 2016 Financial Results Conference Call on Monday, May 16, 2016

Theresa May während der Münchener Sicherheitskonferenz 2018. Foto: Kuhlmann / MSC (https://commons.wikimedia.org/wiki/File:Theresa_May_MSC_2018.jpg), „Theresa May MSC 2018“, Zuschnitt von ARIVA.DE, https://creativecommons.org/licenses/by/3.0/de/legalcode

PR Newswire

LAWRENCEVILLE, N.J., May 9, 2016

LAWRENCEVILLE, N.J., May 9, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2016 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Monday, May 16, 2016. To participate in the call, interested parties may dial 1-888-359-3624 (Toll-Free/North America) or 1-719-457-2085 (International/Toll) and ask for the Celsion Corporation 1^st Quarter 2016 Earnings Call (Conference Code: 7064110) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at www.celsion.com.

The call will be archived for replay on Monday, May 16, 2016 and will remain available until Monday, May 30, 2016. The replay can be accessed at 1-888-203-1112 (Toll-Free/North America) or 1-719-457-0820 (International/Toll) using Conference Code: 7064110. An audio replay of the call will also be available on the Company's website, www.celsion.com, for 30 days after 2:00 p.m. EDT on Monday, May 16, 2016.

About Celsion Corporation

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas™ and TheraSilence™. For more information on Celsion, visit our website: www.celsion.com (CLSN-FIN).

Celsion Investor Contact

Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/celsion-corporation-to-hold-first-quarter-2016-financial-results-conference-call-on-monday-may-16-2016-300264389.html

ARIVA.DE Börsen-Geflüster

Kurse

Imunon Inc

1,33 $

+1,53%

SOURCE Celsion Corporation

Mehr Nachrichten zur Imunon Inc Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.